Stockscreener 앱 받기
1.27
3.05%
-0.04
전일 마감가:
$1.31
열려 있는:
$1.33
하루 거래량:
11.56M
Relative Volume:
1.36
시가총액:
$348.10M
수익:
$188.87M
순이익/손실:
$-400.38M
주가수익비율:
-0.8467
EPS:
-1.5
순현금흐름:
$-260.90M
1주 성능:
+5.83%
1개월 성능:
+24.51%
6개월 성능:
-35.53%
1년 성능:
-19.11%
1일 변동 폭
$1.23
$1.34
1주일 범위
$1.16
$1.40
52주 변동 폭
$0.8511
$2.72
퍼시픽 바이오 사이언스 Stock (PACB) Company Profile
명칭
Pacific Biosciences Of California Inc
전화
650-521-8000
주소
1305 O'BRIEN DRIVE, MENLO PARK, CA
PACB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PACB
Pacific Biosciences Of California Inc
|
1.27 | 348.10M | 188.87M | -400.38M | -260.90M | -1.50 |
|
ABT
Abbott Laboratories
|
132.99 | 233.36B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
101.30 | 147.06B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
375.56 | 145.64B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
86.34 | 112.76B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
73.83 | 44.46B | 5.54B | 4.18B | 623.10M | 7.00 |
퍼시픽 바이오 사이언스 Stock (PACB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-11 | 다운그레이드 | UBS | Buy → Neutral |
| 2024-06-03 | 재개 | Jefferies | Buy |
| 2024-04-22 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-04-18 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-12-14 | 개시 | Guggenheim | Neutral |
| 2023-12-14 | 개시 | Stephens | Overweight |
| 2023-12-13 | 개시 | Wolfe Research | Peer Perform |
| 2023-11-17 | 업그레이드 | UBS | Neutral → Buy |
| 2023-10-31 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2023-09-28 | 개시 | Bernstein | Outperform |
| 2023-07-05 | 재개 | JP Morgan | Overweight |
| 2023-06-30 | 개시 | Goldman | Buy |
| 2023-05-10 | 개시 | Barclays | Equal Weight |
| 2023-03-31 | 업그레이드 | TD Cowen | Market Perform → Outperform |
| 2023-02-02 | 개시 | UBS | Neutral |
| 2023-01-20 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-01-05 | 개시 | Scotiabank | Sector Outperform |
| 2022-01-21 | 재개 | Cantor Fitzgerald | Overweight |
| 2022-01-06 | 재개 | Piper Sandler | Neutral |
| 2021-10-15 | 재개 | Cowen | Market Perform |
| 2021-09-27 | 개시 | Canaccord Genuity | Buy |
| 2021-02-11 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2020-11-03 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2020-10-02 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2020-09-09 | 개시 | Morgan Stanley | Equal-Weight |
| 2020-06-02 | 재개 | Cantor Fitzgerald | Overweight |
| 2020-03-09 | 재개 | Cantor Fitzgerald | Overweight |
| 2019-10-15 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2019-04-02 | 다운그레이드 | Stephens | Overweight → Equal-Weight |
| 2018-10-19 | 개시 | Cowen | Outperform |
| 2017-11-03 | 다운그레이드 | First Analysis Sec | Overweight → Equal-Weight |
| 2017-09-28 | 다운그레이드 | CL King | Buy → Neutral |
| 2016-11-03 | 재확인 | Cantor Fitzgerald | Buy |
| 2016-06-27 | 개시 | CL King | Buy |
| 2016-04-15 | 개시 | First Analysis Sec | Overweight |
| 2016-02-04 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2016-01-04 | 재확인 | Cantor Fitzgerald | Buy |
| 2015-10-23 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2015-08-27 | 개시 | Cantor Fitzgerald | Buy |
| 2015-02-04 | 재확인 | Maxim Group | Buy |
| 2013-09-26 | 재확인 | Maxim Group | Buy |
| 2013-01-14 | 재확인 | Maxim Group | Buy |
모두보기
퍼시픽 바이오 사이언스 주식(PACB)의 최신 뉴스
Here's Why You Should Add PacBio Stock to Your Portfolio Now - MSN
Pacific Biosciences of California (PACB) Outperforms Broader Market: What You Need to Know - Yahoo Finance
Following a 41% decline over last year, recent gains may please Pacific Biosciences of California, Inc. (NASDAQ:PACB) institutional owners - simplywall.st
Celebrating Father’s Day with new discoveries of the Y chromosome achieved with HiFi sequencing - PacBio
Transcript : Pacific Biosciences of California, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 10 - MarketScreener
PACB Q1 Earnings Call: Cost Reductions and Clinical Adoption Offset Market Headwinds - Yahoo Finance
Pacific Biosciences Approves Key Proposals at Annual Meeting - TipRanks
Powered by PacBio: Selected publications from May 2025 - PacBio
Pacific Biosciences Of California To Present At Jefferies Conference; Webcast At 8:45 AM ET - Nasdaq
Amgen To Present At Jefferies Healthcare Conference; Webcast At 9:20 AM ET - Nasdaq
Q1 Earnings Roundup: PacBio (NASDAQ:PACB) And The Rest Of The Life Sciences Tools & Services Segment - Yahoo Finance
Pacific Biosciences of California, Target ALS Collaborate for Genomic Study - marketscreener.com
PacBio (PACB) Joins Forces with Target ALS for Major Genomic Study | PACB Stock News - GuruFocus
Target ALS Chooses PacBio HiFi Sequencing to Advance ALS Research with Largest Global Genomic Study to Date - marketscreener.com
Pacific Biosciences of California: Sell Before Potential Reverse Split - Seeking Alpha
Shareholder Rights Advocates at Levi & Korsinsky Investigate Pacific Biosciences of California, Inc. (PACB) Regarding Possible Securities Fraud Violations - ACCESS Newswire
Media resourceS - PacBio
All You Need to Know About Pacific Biosciences (PACB) Rating Upgrade to Buy - sharewise
PureTarget repeat expansion and carrier panels enable high-throughput clinical research solutions - PacBio
PacBio to Present at Upcoming Investor Conferences - Yahoo Finance
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Q1 2025 Earnings Call Transcript - MSN
PacBio Stock Slips Despite New China Distribution Deal With Haorui - sharewise
PACB stock touches 52-week low at $0.94 amid market challenges - Investing.com Australia
PacBio (PACB) Expands Presence in China with New Distribution De - GuruFocus
PacBio (PACB) Expands Presence in China with New Distribution Deal | PACB Stock News - GuruFocus
PacBio Expands Distribution in China, Gaining Access to New Clinical Lab Networks via Haorui Gene - Yahoo Finance
HiFi sequencing uncovers the secret to aging gracefully in Earth’s oldest living organisms - PacBio
Pacific Biosciences: A Mountain Of Red Flags (NASDAQ:PACB) - Seeking Alpha
Potential Upside For Pacific Biosciences of California, Inc. (NASDAQ:PACB) Not Without Risk - simplywall.st
PACB: Piper Sandler Adjusts Price Target for Pacific Biosciences - GuruFocus
PACB: Piper Sandler Adjusts Price Target for Pacific Biosciences | PACB Stock News - GuruFocus
PACB: Stephens & Co. Reiterates Overweight Rating | PACB Stock N - GuruFocus
Where Pacific Biosciences Stands With Analysts - Benzinga
PACB: Stephens & Co. Reiterates Overweight Rating | PACB Stock News - GuruFocus
PACB Price Target Reduced by Piper Sandler Following Quarterly R - GuruFocus
PACB Price Target Reduced by Piper Sandler Following Quarterly Results | PACB Stock News - GuruFocus
PacBio clears allegations after special investigation By Investing.com - Investing.com Nigeria
Metagenomics Market Size, Share, Forecast & Trends Analysis Report 2025: Market to Soar to $6.71 Billion by 2031, Driven by Agri Genomics and Genome Mapping - GlobeNewswire Inc.
PACB Stock May Rise Following the Deal With Chulalongkorn University - Nasdaq
PacBio (PACB) Completes Probe into Employment Practices and Cybe - GuruFocus
PacBio Board Independent Investigation Concludes Allegations Unsubstantiated - Yahoo Finance
Pacbio adjusts 2025 revenue guidance to $150M-$170M amid macroeconomic challenges - MSN
Pacific Biosciences of California First Quarter 2025 Earnings: EPS Misses Expectations - Yahoo Finance
PacBio (PACB) Sees Increased Options Activity Ahead of Earnings - GuruFocus
PacBio Stock Down Despite Q1 Earnings & Revenue Beat Estimates - Yahoo Finance
퍼시픽 바이오 사이언스 (PACB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
퍼시픽 바이오 사이언스 주식 (PACB) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| HENRY CHRISTIAN O | See Remarks |
Mar 03 '25 |
Sale |
1.41 |
12,497 |
17,583 |
2,225,357 |
| Van Oene Mark | See Remarks |
Mar 03 '25 |
Sale |
1.41 |
6,486 |
9,126 |
1,497,695 |
| Farmer Michele | See Remarks |
Mar 03 '25 |
Sale |
1.41 |
2,973 |
4,183 |
184,619 |
0.45%
0.24%
자본화:
|
볼륨(24시간):